rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2019-6-3-5rpmj-421Research ArticleОбзорыReviewБИОМАРКЕРЫ, НЕОАНГИОГЕНЕЗ И ФАКТОРЫ РОСТА ПРИ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫBIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCERhttps://orcid.org/0000-0003-3618-6890ФранциянцЕ. М.FrantsiyantsE. M.

д. б.н., профессор, заместитель генерального директора по науке, руководитель лаборатории патогенеза злокачественных опухолей

PhD, DSc (Biology), professor, deputy director general for science, head of laboratory for the study of the pathogenesis of malignant tumors

https://orcid.org/0000-0003-3061-6108КитО. И.KitO. I.

д. м.н., профессор, член-корреспондент РАН, генеральный директор

MD, PhD, DSc, professor

АлейновВ. И.AleynovV. I.

аспирант

postgraduate

https://orcid.org/0000-0001-6265-8500ГорошинскаяИ. А.GoroshinskayaI. A.

д. б.н., профессор, главный научный сотрудник лаборатории патогенеза злокачественных опухолей

PhD, DSc (Biology), Professor, Chief Researcher of the Laboratory of Malignant Tumors Pathogenesis

iagor17@mail.ruФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииРоссияRostov Research Institute of Oncology (RRIO)Russian Federation201904092019635164Copyright © Франциянц Е.М., Кит О.И., Алейнов В.И., Горошинская И.А., 20192019Франциянц Е.М., Кит О.И., Алейнов В.И., Горошинская И.А.Frantsiyants E.M., Kit O.I., Aleynov V.I., Goroshinskaya I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/421

Рак поджелудочной железы – летальная злокачественная опухоль, характеризующаяся быстрой прогрессией, инвазивностью и резистентностью к противоопухолевому лечению. Актуальна разработка биомаркеров для ранней диагностики заболевания. Ангиогенез идентифицирован как ключевой фактор в ряде патологических состояний, включая рак. Центральная роль в ангиогенезе опухолей принадлежит проангиогенной сигнальной молекуле – фактору роста эндотелия сосудов (VEGF) и его рецепторам. В этом обзоре мы также выделили двойную роль фактора роста-β (TGF-β) и перспективы терапевтических воздействий, влияющих на передачу сигналов TGF-β при раке поджелудочной железы. Растет интерес к инсулиноподобным факторам роста IGF-I и IGF-II при онкологических заболеваниях. Показана высоковыраженная экспрессия IGF-I и его рецептора на поверхности линий клеток рака поджелудочной железы, что инициирует трансдукцию внутриклеточных сигналов, связанную с пролиферацией, инвазией и экспрессией медиаторов ангиогенеза. Таким образом, исследование маркеров и факторов роста может быть новым, приемлемым для практики вариантом диагностики и лечения рака поджелудочной железы.

Pancreatic cancer (PC) is a lethal malignant tumor characterized by a rapid progression, invasiveness and resistance to radiochemotherapy. The development of biomarkers for the early diagnosis of the disease is relevant. Angiogenesis has been identified as a key factor in a number of pathological conditions, including cancer. The proangiogenic signaling molecule – vascular endothelial growth factor (VEGF) and its receptors play a central role in tumor angiogenesis. In this review, we also highlight the dual role of growth factor-β (TGF-β) and touch upon the prospects for therapeutic effects on targets associated with TGF-β signaling in pancreatic cancer. A growing interest is attracted to the role of insulin-like growth factors IGF-I and IGF-II in cancer diseases. IGF-I and its receptor are highly expressed on the surface of pancreatic cancer cell lines that initiate the transduction of intracellular signals associated with the proliferation, invasion and expression of angiogenesis mediators. And so, the study of markers and growth factors may be a new, viable option for the diagnosis and treatment of pancreatic cancer.

рак поджелудочной железыбиомаркерыангиогенезVEGFVEGFRтрансформирующий фактор роста-βинсулиноподобный фактор ростаpancreatic cancerbiomarkersangiogenesisVEGFVEGFRtransforming growth factor-βinsulin-like growth factorДанная работа проводилась в рамках выполнения тем государственного задания ФГБУ «РНИОИ» Минздрава России за 2018–2020 гг.This work was carried out in the framework of the state task of the Rostov Research Institute of Oncology (RRIO) for 2018–2020.ReferencesFerlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356–387. DOI: 10.1016/j.ejca.2018.07.005Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Esti-mates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356–387. DOI: 10.1016/j.ejca.2018.07.005Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66 (1):7–30. DOI: 10.3322/caac.21332Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66 (1):7–30. DOI: 10.3322/caac.21332Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой М., 2018. Доступно по: http:// docplayer.ru/68451567-Zlokachestvennye-novoobrazovaniyav-rossii-v-2016-godu.html. Дата обращения 09.04.2019.Malignant neoplasms in Russia in 2016 (morbidity and mortality). Edited by Kaprin AD, Starinskii VV, Petrova GV. Moscow, 2018. Available at: http://docplayer.ru/68451567-Zlokachestvennye-novoobrazovaniya-v-rossii-v-2016-godu.html. Accessed 09.04.2019 (In Russian).Martinez-Users J, Li W, Cabeza-Morales M, Garcia-Foncillas J. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. J Clin Med. 2017 Mar 9;6 (3). pii: E29. DOI: 10.3390/jcm6030029.Martinez-Users J, Li W, Cabeza-Morales M, Garcia-Foncillas J. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. J Clin Med. 2017 Mar 9;6 (3). pii: E29. DOI: 10.3390/jcm6030029Hidalgo M. Pancreatic cancer. N Engl J Med. 2010 Apr 29;362 (17):1605–17. DOI: 10.1056/NEJMra0901557Hidalgo M. Pancreatic cancer. N Engl J Med. 2010 Apr 29;362 (17):1605–17. DOI: 10.1056/NEJMra0901557Алибегов Р. А., Нарезкин Д. В., Сергеев О. А., Прохоренко Т. И., Жвитиашвили И. Д. Ранние послеоперационные осложнения панкреатодуоденальных резекций. Хирургия. Восточная Европа. 2012;3 (3):321–2.Alibegov RA, Narezkin DV, Sergeev OA, Prohorenko TI, Zhvitiashvili ID. Early postoperative complications of pancreatoduodenal resection. Surgery. Eastern Europe. 2012;3 (3):321–2. (In Russian).Кочатков А. В., Кубышкин В. А., Гуревич Л. Е., Буриев И. М., Балукова О. В., Савелов Н. А., и др. Прогнозирование течения рака поджелудочной железы: значение молекулярно-генетических нарушений в опухолевых клетках. Анналы хирургической гепатологии. 2007;12 (1):68–75.Kochatkov AV, Kubyshkin VA, Gurevich LE, Buriev IM, Balukova OV, Savelov NA, et al. Pancreatic Cancer Course Prognosis: Significance of Molecular-genetic Alterations in the Cancer Cells. Annaly khirurgicheskoy gepatologii (Annals of Surgical Hepatology). 2007;12 (1):68–75. (In Russian).Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379 (25):2395– 2406. DOI: 10.1056/NEJMoa1809775Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379 (25):2395– 2406. DOI: 10.1056/NEJMoa1809775Покатаев И. А., Алиева С. Б., Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Патютко Ю. И., и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018;8 (3s2):401–13.Pokataev IA, Alieva SB, Gladkov OA, Zagajnov VE, Kudashkin NE, Patjutko JuI, et al. Practical recommendations for drug treatment of pancreatic cancer. Malignant tumours. 2018;8 (3s2):401–13. (In Russian).Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: Prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008 Jan;134 (1):95–101. DOI: 10.1053/j.gastro.2007.10.040Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: Prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008 Jan;134 (1):95–101. DOI: 10.1053/j.gastro.2007.10.040Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int J Epidemiol. 2015 Feb;44 (1):186–98. DOI: 10.1093/ije/dyu240Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int J Epidemiol. 2015 Feb;44 (1):186–98. DOI: 10.1093/ije/dyu240Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015 Feb;42 (1):8–18. DOI: 10.1053/j.seminoncol.2014.12.002Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015 Feb;42 (1):8–18. DOI: 10.1053/j.seminoncol.2014.12.002Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: Meta-analysis of prospective studies. Br J Cancer. 2012 Jan 31;106 (3):603–7. DOI: 10.1038/ bjc.2011.585.Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: Meta-analysis of prospective studies. Br J Cancer. 2012 Jan 31;106 (3):603–7. DOI: 10.1038/bjc.2011.585.Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N, et al. Pancreatic cancer risk and levels of trace elements. Gut. 2012 Nov;61 (11):1583–8. DOI: 10.1136/gutjnl-2011–301086Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N, et al. Pancreatic cancer risk and levels of trace elements. Gut. 2012 Nov;61 (11):1583–8. DOI: 10.1136/gutjnl-2011–301086Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19–9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004 Feb;19 (2):182–6.Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19–9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004 Feb;19 (2):182–6.Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, et al. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. J Natl Cancer Inst. 2019 Apr 1;111 (4):372–379. DOI: 10.1093/jnci/djy126Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, et al. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. J Natl Cancer Inst. 2019 Apr 1;111 (4):372–379. DOI: 10.1093/jnci/djy126Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018 Jan;67 (1):128–137. DOI: 10.1136/gutjnl-2016–312432Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018 Jan;67 (1):128–137. DOI: 10.1136/gutjnl-2016–312432Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016 Mar;10 (3):481–93. DOI: 10.1016/j.molonc.2016.01.006Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016 Mar;10 (3):481–93. DOI: 10.1016/j.molonc.2016.01.006Princivalle A, Monasta L, Butturini G, Bassi C, Perbellini L. Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air. BMC Cancer. 2018 May 4;18 (1):529. DOI: 10.1186/s12885–018–4452–0Princivalle A, Monasta L, Butturini G, Bassi C, Perbellini L. Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air. BMC Cancer. 2018 May 4;18 (1):529. DOI: 10.1186/s12885–018–4452–0Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013 Jun;11 (6):719–30.e5. DOI: 10.1016/j. cgh.2012.11.016.Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013 Jun;11 (6):719–30.e5. DOI: 10.1016/j. cgh.2012.11.016.Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol. 2013 Apr;27 (2):299–322. DOI: 10.1016/j.bpg.2013.04.001.Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol. 2013 Apr;27 (2):299–322. DOI: 10.1016/j.bpg.2013.04.001.Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, et al. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 2017 Jul 15;141 (2):231–241. DOI: 10.1002/ijc.30670Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, et al. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 2017 Jul 15;141 (2):231–241. DOI: 10.1002/ijc.30670Кит О. И., Франциянц Е. М., Козлова Л. С., Мезенцев С. С., Газиев У. М., авторы; ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России, патентообладатель. Способ прогнозирования направленности патологического процесса при раке головки поджелудочной железы. Патент Российской Федерации 2612082. 14 октября 2015; опубл. 2.03.2017, Бюл. № 7.Kit OI, Frantsiyants EM, Kozlova LS, Mezentsev SS, Gaziev UM, inventors; Rostov Research Institute of Oncology, assignee. Sposob prognozirovanija napravlennosti patologicheskogo processa pri rake golovki podzheludochnoj zhelezy [A method for predicting the orientation of the pathological process in cancer of the pancreatic head] Russian Federation patent RU 2612082. 2015 Nov 14. (In Russian).Кит О. И., Франциянц Е. М., Козлова Л. С., Колесников Е. Н., Газиев У. М., авторы; ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России, патентообладатель. Способ прогнозирования предрасположенности к послеоперационному кровотечению при раке головки поджелудочной железы. Патент Российской Федерации 2613308. 23 ноября 2015; опубл. 15.03.2017, Бюл. № 8.Kit OI, Frantsiyants EM, Kozlova LS, Kolesnikov EN, Gaziev UM, inventors; Rostov Research Institute of Oncology, assignee. Sposob prognozirovanija predraspolozhennosti k posleoperacionnomu krovotecheniju pri rake golovki podzheludochnoj zhelezy [A method for predicting susceptibility to postoperative bleeding in cancer of the pancreatic head] Russian Federation patent RU 2613308. 2015 Nov 23. (In Russian).Кит О. И., Франциянц Е. М., Козлова Л. С., Колесников Е. Н., Газиев У. М., авторы; ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России, патентообладатель. Способ прогнозирования развития острого послеоперационного панкреатита культи поджелудочной железы после панкреатодуоденальной резекции у онкологических больных. Патент Российской Федерации 2616183. 16 ноября 2015; опубл. 13.04.2017, Бюл. № 11.Kit OI, Frantsiyants EM, Kozlova LS, Kolesnikov EN, Gaziev UM, inventors; Rostov Research Institute of Oncology, assignee. Sposob prognozirovanija razvitija ostrogo posleoperacionnogo pankreatita kul’ti podzheludochnoj zhelezy posle pankreatoduodenal’noj rezekcii u onkologicheskih bol’nyh [A method for predicting the development of acute postoperative pancreatitis stump of the pancreas aſter pancreatoduodenal resection in cancer patients] Russian Federation patent RU 2616183. 2015 Nov 16. (In Russian).Кит О. И., Франциянц Е. М., Козлова Л. С., Мезенцев С. С., Газиев У. М., авторы; ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России, патентообладатель. Способ прогнозирования развития острого послеоперационного панкреатита культи поджелудочной железы после панкреатодуоденальной резекции у онкологических больных. Патент Российской Федерации 2618402. 23 ноября 2015; опубл. 03.05.2017, Бюл. № 13.Kit OI, Frantsiyants EM, Kozlova LS, Mezentsev SS, Gaziev UM, inventors; Rostov Research Institute of Oncology, assignee. Sposob prognozirovanija razvitija ostrogo posleoperacionnogo pankreatita kul’ti podzheludochnoj zhelezy posle pankreatoduodenal’noj rezekcii u onkologicheskih bol’nyh [A method for predicting the development of acute postoperative pancreatitis stump of the pancreas aſter pancreatoduodenal resection in cancer patients] Russian Federation patent RU 2618402. 2015 Nov 23. (In Russian).Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007 Apr;6 (4):273–86. DOI: 10.1038/nrd2115Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007 Apr;6 (4):273–86. DOI: 10.1038/nrd2115Davis GE, Senger DR. Endothelial extracellular matrix biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005 Nov 25;97 (11):1093– 107. DOI: 10.1161/01.RES.0000191547.64391.e3Davis GE, Senger DR. Endothelial extracellular matrix biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005 Nov 25;97 (11):1093– 107. DOI: 10.1161/01.RES.0000191547.64391.e3Yehya A, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid A, et al. Angiogenesis: managing the culprits behind tumorigenesis and metastasis. Medicina (Kaunas). 2018 Mar 25;54 (1). pii: E8. DOI: 10.3390/medicina54010008.Yehya A, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid A, et al. Angiogenesis: managing the culprits behind tumorigenesis and metastasis. Medicina (Kaunas). 2018 Mar 25;54 (1). pii: E8. DOI: 10.3390/medicina54010008.Monahan-Earley R, Dvorak A, Aird W. Evolutionary origins of the blood vascular system and endothelium. J Thromb Haemost. 2013;11 (1):46–66. DOI: 10.1111/jth.12253Monahan-Earley R, Dvorak A, Aird W. Evolutionary origins of the blood vascular system and endothelium. J Thromb Haemost. 2013;11 (1):46–66. DOI: 10.1111/jth.12253Williams PA. Manipulating endothelial progenitor cell homing with sphingosine-1-phosphate for terapeutic angiogenesis [dissertation]. Davis, CA, USA: University of California; 2016.Williams PA. Manipulating endothelial progenitor cell homing with sphingosine-1-phosphate for terapeutic angiogenesis [dissertation]. Davis, CA, USA: University of California; 2016.Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, et al. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget. 2017;8 (25):40115–31. DOI: 10.18632/oncotarget.16969Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, et al. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget. 2017;8 (25):40115–31. DOI: 10.18632/oncotarget.16969Eelen G, de Zeeuw P, Simons M, Carmeliet P. Endothelial cell metabolism in normal and diseased vasculature. Circ Res. 2015;116 (7):1231–44. DOI: 10.1161/circresaha.116.302855Eelen G, de Zeeuw P, Simons M, Carmeliet P. Endothelial cell metabolism in normal and diseased vasculature. Circ Res. 2015;116 (7):1231–44. DOI: 10.1161/circresaha.116.302855Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25 (4):198–213. DOI: 10.1016/j.tcb.2014.11.006Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25 (4):198–213. DOI: 10.1016/j.tcb.2014.11.006Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol. 2015;35 (Suppl): S224-S243. DOI: 10.1016/j.semcancer.2015.01.001Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol. 2015;35 (Suppl): S224-S243. DOI: 10.1016/j.semcancer.2015.01.001Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8 (6):464–78. DOI: 10.1038/nrm2183Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8 (6):464–78. DOI: 10.1038/nrm2183Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia. 2016;59:1616–20. DOI: 10.1007/s00125–016–3995–3Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia. 2016;59:1616–20. DOI: 10.1007/s00125–016–3995–3Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3 (2):140–55.Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3 (2):140–55.Gallach S, Calabuig-Farinas S, Jantus-Lewintre E, Camps C. MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int. 2014;2014:878450. DOI: 10.1155/2014/878450Gallach S, Calabuig-Farinas S, Jantus-Lewintre E, Camps C. MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int. 2014;2014:878450. DOI: 10.1155/2014/878450Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, et al. MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget. 2015 Jan 1;6 (1):471–83. DOI: 10.18632/oncotarget.2509Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, et al. MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget. 2015 Jan 1;6 (1):471–83. DOI: 10.18632/oncotarget.2509Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015 Sep 15;6 (27):23323–41. DOI: 10.18632/oncotarget.4492Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015 Sep 15;6 (27):23323–41. DOI: 10.18632/oncotarget.4492Yoo SY, Kwon SM. Angiogenesis and its therapeutic opportunities. Mediators Inflamm. 2013;2013:127170. DOI: 10.1155/2013/127170Yoo SY, Kwon SM. Angiogenesis and its therapeutic opportunities. Mediators Inflamm. 2013;2013:127170. DOI: 10.1155/2013/127170Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoff-mann S, Drexler HC, et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013;15:249–60. DOI: 10.1038/ncb2679Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler HC, et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013;15:249–60. DOI: 10.1038/ncb2679Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23 (5):1011–27. DOI: 10.1200/JCO.2005.06.081Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23 (5):1011–27. DOI: 10.1200/JCO.2005.06.081Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013 Jan 15;73 (2):539–49. DOI: 10.1158/0008–5472. CAN-12–2325Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013 Jan 15;73 (2):539–49. DOI: 10.1158/0008–5472. CAN-12–2325Kubatka P, Kapinová A, Kello M, Kruzliak P, Kajo K, Výbohová D, et al. Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer. Eur J Nutr. 2016 Apr;55 (3):955–65. DOI: 10.1007/s00394–015–0910–5Kubatka P, Kapinová A, Kello M, Kruzliak P, Kajo K, Výbohová D, et al. Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer. Eur J Nutr. 2016 Apr;55 (3):955–65. DOI: 10.1007/s00394–015–0910–5Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Longatto Filho A. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013 Mar-Apr;10 (2):55–67Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Longatto Filho A. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013 Mar-Apr;10 (2):55–67Matsumoto M, Roufail S, Inder R, Caesar C, Karnezis T, Shayan R, et al. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis. 2013 Aug;30 (6):819–32. DOI: 10.1007/s10585–013–9581-xMatsumoto M, Roufail S, Inder R, Caesar C, Karnezis T, Shayan R, et al. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis. 2013 Aug;30 (6):819–32. DOI: 10.1007/s10585–013–9581-xLi J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34 (13):1448–54. DOI: 10.1200/JCO.2015.63.5995Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34 (13):1448–54. DOI: 10.1200/JCO.2015.63.5995Siemann D, Chaplin D, Horsman M. Realizing the potential of vascular targeted therapy: The rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer. Cancer Invest. 2017 Sep 14;35 (8):519–534. DOI: 10.1080/07357907.2017.1364745Siemann D, Chaplin D, Horsman M. Realizing the potential of vascular targeted therapy: The rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer. Cancer Invest. 2017 Sep 14;35 (8):519–534. DOI: 10.1080/07357907.2017.1364745David CJ, Massague J. Contextual determinants of TGFbeta action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018 Jul;19 (7):419–435. DOI: 10.1038/s41580–018–0007–0David CJ, Massague J. Contextual determinants of TGFbeta action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018 Jul;19 (7):419–435. DOI: 10.1038/s41580–018–0007–0Colak S, Ten Dijke P. Targeting TGF-beta signaling in cancer. Trends Cancer. 2017;3 (1):56–71. DOI: 10.1016/j.trecan.2016.11.008.Colak S, Ten Dijke P. Targeting TGF-beta signaling in cancer. Trends Cancer. 2017;3 (1):56–71. DOI: 10.1016/j.trecan.2016.11.008.Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, et al. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014 Jan 20;9 (1): e85942. DOI: 10.1371/journal. pone.0085942Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, et al. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014 Jan 20;9 (1): e85942. DOI: 10.1371/journal. pone.0085942Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, et al. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma. Braz J Med Biol Res. 2016;49 (8): e5485. DOI: 10.1590/1414– 431X20165485Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, et al. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma. Braz J Med Biol Res. 2016;49 (8): e5485. DOI: 10.1590/1414– 431X20165485Zhang H, Liu C, Kong Y, Huang H, Wang C, Zhang H. TGFbeta signaling in pancreatic ductal adenocarcinoma. Tumour Biol. 2015 Mar;36 (3):1613–8. DOI: 10.1007/s13277–014–2757–4Zhang H, Liu C, Kong Y, Huang H, Wang C, Zhang H. TGFbeta signaling in pancreatic ductal adenocarcinoma. Tumour Biol. 2015 Mar;36 (3):1613–8. DOI: 10.1007/s13277–014–2757–4Shen W, Tao GQ, Zhang Y, Cai B, Sun J, Tian ZQ. TGF-beta in pancreatic cancer initiation and progression: two sides of the same coin. Cell Biosci. 2017 Aug 7;7:39. DOI: 10.1186/s13578– 017–0168–0Shen W, Tao GQ, Zhang Y, Cai B, Sun J, Tian ZQ. TGF-beta in pancreatic cancer initiation and progression: two sides of the same coin. Cell Biosci. 2017 Aug 7;7:39. DOI: 10.1186/s13578– 017–0168–0Glazer ES, Welsh E, Pimiento JM, Teer JK, Malafa MP. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Oncotarget. 2017 Jan 3;8 (1):999–1006. DOI: 10.18632/oncotarget.13533Glazer ES, Welsh E, Pimiento JM, Teer JK, Malafa MP. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Oncotarget. 2017 Jan 3;8 (1):999–1006. DOI: 10.18632/oncotarget.13533Lin X, Feng XH. Abrogation of transforming growth factor-beta signaling in pancreatic cancer. World J Surg. 2005;29 (3):312–6. DOI: 10.1007/s00268–004–7824–3.Lin X, Feng XH. Abrogation of transforming growth factor-beta signaling in pancreatic cancer. World J Surg. 2005;29 (3):312–6. DOI: 10.1007/s00268–004–7824–3.Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci. 2010 Jan 1;6 (1):1–8. DOI: 10.7150/ijbs.6.1Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci. 2010 Jan 1;6 (1):1–8. DOI: 10.7150/ijbs.6.1Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel). 2016;8 (4):45. DOI: 10.3390/cancers8040045Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel). 2016;8 (4):45. DOI: 10.3390/cancers8040045Leung L, Radulovich N, Zhu CQ, Wang D, To C, Ibrahimov E, et al. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis. PLoS One. 2013 Dec 27;8 (12): e84366. DOI: 10.1371/journal.pone.0084366Leung L, Radulovich N, Zhu CQ, Wang D, To C, Ibrahimov E, et al. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis. PLoS One. 2013 Dec 27;8 (12): e84366. DOI: 10.1371/journal.pone.0084366Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111 (5):817–22. DOI: 10.1038/bjc.2014.215Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111 (5):817–22. DOI: 10.1038/bjc.2014.215Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554 (7690):62–8. DOI: 10.1038/nature25459Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554 (7690):62–8. DOI: 10.1038/nature25459Gore AJ, Deitz SL, Palam LR, Craven KE, Korc M. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation. J Clin Invest. 2014;124 (1):338–52. DOI: 10.1172/JCI71526Gore AJ, Deitz SL, Palam LR, Craven KE, Korc M. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation. J Clin Invest. 2014;124 (1):338–52. DOI: 10.1172/JCI71526Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer. 2011;10:67. DOI: 10.1186/1476–4598–10–67Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer. 2011;10:67. DOI: 10.1186/1476–4598–10–67Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013;13 (11):788–99. DOI: 10.1038/nrc3603Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013;13 (11):788–99. DOI: 10.1038/nrc3603Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett. 2013;341 (1):30–40. DOI: 10.1016/j.canlet.2013.02.048Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett. 2013;341 (1):30–40. DOI: 10.1016/j.canlet.2013.02.048Zarzynska JM. Two faces of TGF-beta1 in breast cancer. Mediators Inflamm. 2014;2014:141747. DOI: 10.1155/2014/141747Zarzynska JM. Two faces of TGF-beta1 in breast cancer. Mediators Inflamm. 2014;2014:141747. DOI: 10.1155/2014/141747Melzer C, Hass R, von der Ohe J, Lehnert H, Ungefroren H. The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma. Cell communication and signaling. Cell Communication and Signaling. 2017;15 (1):19. DOI: 10.1186/s12964–017–0175–0Melzer C, Hass R, von der Ohe J, Lehnert H, Ungefroren H. The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma. Cell communication and signaling. Cell Communication and Signaling. 2017;15 (1):19. DOI: 10.1186/s12964–017–0175–0Luo J, Chen XQ, Li P. The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl Oncol. 2019 Mar;12 (3):475–484. DOI: 10.1016/j.tranon.2018.11.010Luo J, Chen XQ, Li P. The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl Oncol. 2019 Mar;12 (3):475–484. DOI: 10.1016/j.tranon.2018.11.010Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8 (12):915–28. DOI: 10.1038/nrc2536Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8 (12):915–28. DOI: 10.1038/nrc2536Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014 Jan 1;6 (1). pii: a009191. DOI: 10.1101/cshperspect.a009191Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014 Jan 1;6 (1). pii: a009191. DOI: 10.1101/cshperspect.a009191Rajapaksha H, Forbes BE. Ligand-binding affinity at the insulin receptor Isoform-a and subsequent IR-A tyrosine Phosphorylation kinetics are important determinants of Mitogenic biological outcomes. Front Endocrinol (Lausanne). 2015;6:107. DOI: 10.3389/ fendo.2015.00107Rajapaksha H, Forbes BE. Ligand-binding affinity at the insulin receptor Isoform-a and subsequent IR-A tyrosine Phosphorylation kinetics are important determinants of Mitogenic biological outcomes. Front Endocrinol (Lausanne). 2015;6:107. DOI: 10.3389/fendo.2015.00107Mutgan AC, Besikcioglu HE, Wang S, Friess H, Ceyhan GO, Demir IE. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Mol Cancer. 2018 Feb 23;17 (1):66. DOI: 10.1186/s12943–018–0806–0.Mutgan AC, Besikcioglu HE, Wang S, Friess H, Ceyhan GO, Demir IE. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Mol Cancer. 2018 Feb 23;17 (1):66. DOI: 10.1186/s12943–018–0806–0.Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, et al. Epidermal growth factor receptor and insulin like growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118 (14):3484–93. DOI: 10.1002/cncr.26661Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, et al. Epidermal growth factor receptor and insulin like growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118 (14):3484–93. DOI: 10.1002/cncr.26661Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019. DOI: 10.1155/2015/538019Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019. DOI: 10.1155/2015/538019Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23 (6):824–54. DOI: 10.1210/er.2001–0033.Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23 (6):824–54. DOI: 10.1210/er.2001–0033.Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14 (5):329–41. DOI: 10.1038/nrc3720.Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14 (5):329–41. DOI: 10.1038/nrc3720.Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P, et al. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol. 2002;83 (5):239–45. DOI: 10.1046/j.1365–2613.2002.00237.xKarna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P, et al. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol. 2002;83 (5):239–45. DOI: 10.1046/j.1365–2613.2002.00237.xDouglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev. 2010;19 (9):2298–306. DOI: 10.1158/1055–9965. EPI-10–0400Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev. 2010;19 (9):2298–306. DOI: 10.1158/1055–9965. EPI-10–0400Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland A, Roswall N, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Br J Cancer. 2012;106 (5):1004–10. DOI: 10.1038/bjc.2012.19Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland A, Roswall N, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Br J Cancer. 2012;106 (5):1004–10. DOI: 10.1038/bjc.2012.19Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer. 2013;13:392. DOI: 10.1186/1471–2407–13–392Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer. 2013;13:392. DOI: 10.1186/1471–2407–13–392Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol. 2002;21 (2):327–35.Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol. 2002;21 (2):327–35.

The authors declare that there are no conflicts of interest present.